ALVO icon

Alvotech

8.87 USD
-0.15
1.66%
Updated Jul 8, 10:58 AM EDT
1 day
-1.66%
5 days
-1.77%
1 month
-16.56%
3 months
10.05%
6 months
-33.06%
Year to date
-32.60%
1 year
-27.00%
5 years
-20.73%
10 years
-20.73%
 

About: Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Employees: 1,032

0
Funds holding %
of 7,311 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

11% more funds holding

Funds holding: 45 [Q4 2024] → 50 (+5) [Q1 2025]

0.41% more ownership

Funds ownership: 5.11% [Q4 2024] → 5.52% (+0.41%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

20% less capital invested

Capital invested by funds: $200M [Q4 2024] → $159M (-$40.7M) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for ALVO.

Financial journalist opinion

Based on 15 articles about ALVO published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
Neutral
GlobeNewsWire
6 days ago
Granting of Stock Options and Vesting of Restricted Share Units
In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company's Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.
Granting of Stock Options and Vesting of Restricted Share Units
Neutral
GlobeNewsWire
1 week ago
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
REYKJAVIK,  ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol).
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
Neutral
GlobeNewsWire
1 week ago
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol).
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
Neutral
GlobeNewsWire
1 week ago
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
Lenders have reduced the rate of interest on Alvotech's loan facility reflecting sustained operational improvements and strengthened financial performance
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
Neutral
GlobeNewsWire
1 week ago
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under the Company's existing senior secured term loan facility, including GoldenTree Asset Management (collectively, the “Lenders”), have agreed to reduce the rate of interest on its existing senior secured term loan facility (the “Facility”). The agreement will lower Alvotech's interest payments in the first 12 months by an estimated US$8.2 million. This is an outcome of Alvotech's sustained operational improvements and strengthened financial performance over the past year.
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
Neutral
GlobeNewsWire
1 week ago
Main Results of 2025 Annual and Extraordinary General Meeting
REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.
Main Results of 2025 Annual and Extraordinary General Meeting
Neutral
GlobeNewsWire
1 week ago
Main Results of 2025 Annual and Extraordinary General Meeting
The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.
Main Results of 2025 Annual and Extraordinary General Meeting
Neutral
GlobeNewsWire
1 week ago
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
Neutral
GlobeNewsWire
1 week ago
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK,  ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
Charts implemented using Lightweight Charts™